VERTEX PHARMACEUTICALS INC / MA Quarterly Deferred Tax Assets, Net of Valuation Allowance in USD from Q4 2011 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly Deferred Tax Assets, Net of Valuation Allowance history and growth rate from Q4 2011 to Q4 2023.
  • Vertex Pharmaceuticals Inc / Ma Deferred Tax Assets, Net of Valuation Allowance for the quarter ending December 31, 2023 was $2.17B, a 34.9% increase year-over-year.
Deferred Tax Assets, Net of Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Net of Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $2.17B +$561M +34.9% Dec 31, 2023 10-K 2024-02-15
Q4 2022 $1.61B +$347M +27.5% Dec 31, 2022 10-K 2024-02-15
Q4 2021 $1.26B +$78.1M +6.6% Dec 31, 2021 10-K 2023-02-10
Q4 2020 $1.18B -$238M -16.8% Dec 31, 2020 10-K 2022-02-09
Q4 2019 $1.42B -$290M -17% Dec 31, 2019 10-K 2021-02-11
Q4 2018 $1.71B +$1.53B +843% Dec 31, 2018 10-K 2020-02-13
Q4 2017 $182M -$69.1M -27.6% Dec 31, 2017 10-K 2019-02-13
Q4 2016 $251M +$73.9M +41.8% Dec 31, 2016 10-K 2018-02-15
Q4 2015 $177M +$17.9M +11.2% Dec 31, 2015 10-K 2017-02-23
Q4 2014 $159M +$24.9M +18.6% Dec 31, 2014 10-K 2016-02-16
Q4 2013 $134M +$133M +21920% Dec 31, 2013 10-K 2015-02-13
Q4 2012 $609K -$229M -99.7% Dec 31, 2012 10-K 2014-02-11
Q4 2011 $230M Dec 31, 2011 10-K 2013-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.